The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.
 
Wangjun Liao
No Relationships to Disclose
 
Min Shi
No Relationships to Disclose
 
Xiaoxiang Rong
No Relationships to Disclose
 
Siting Zheng
No Relationships to Disclose
 
Shaowei Li
No Relationships to Disclose
 
Weiwei Peng
No Relationships to Disclose
 
Xiangcai Wang
No Relationships to Disclose
 
Xia Yuan
No Relationships to Disclose
 
Wei Zeng
No Relationships to Disclose
 
Chunlin Wang
No Relationships to Disclose
 
Qiong Deng
No Relationships to Disclose
 
Futing Zhang
No Relationships to Disclose